

06 NOV 2003

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

162162

(43) International Publication Date
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number
WO 03/076413 A1(51) International Patent Classification⁷: C07D 235/32,
A61K 31/415, C07D 493/04, 235/30, 407/12, 417/12,
413/12, 401/12, A61P 31/1810, B-2370 Arendonk (BE). VERGOUWEN, Bernhard,
Joanna, Bernard [BE/BE]; Rietstraat 13, B-3680 Maaseik
(BE).

(21) International Application Number: PCT/EP03/50057

(74) Agent: DAELEMANS, Frank; Tibotec-Virco Comm.
VA, Generaal De Wittelaan L11B3, B-2800 Mechelen
(BE).

(22) International Filing Date: 12 March 2003 (12.03.2003)

(25) Filing Language: English

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:
02075999.9 12 March 2002 (12.03.2002) EP(71) Applicant (for all designated States except US): TI-
BOTEC PHARMACEUTICALS LTD [IE/IE]; Unit 4,
Block 4B, Blanchardstown Corporate Park, Blanchard-
stown, 15 Dublin (IE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SURLERAUX, Do-
minique, Louis, Nestor, Ghislain [BE/BE]; Diegemstraat
48, B-1830 Machelen (BE). WIGERINCK, Piet, Tom,
Bert, Paul [BE/BE]; Kardinaal Cardijnstraat 29, B-2840
Terhagen (BE). VOETS, Marieke, Christiane, Johanna
[BE/BE]; Visserijstraat 29, B-3590 Diepenbeek (BE).
VENDEVILLE, Sandrine, Marie, Helene [FR/BE];
Square Marguerite, 14 - Boîte 18, B-1000 Bruxelles (BE).
DE KOCK, Herman, Augustinus [BE/BE]; Wolfseind(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

[Continued on next page]

(54) Title: BROADSPECTRUM SUBSTITUTED BENZIMIDAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS



(57) Abstract: The present invention concerns the compounds having the formula (I), wherein N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R₁ and R₈ each are H, optionally substituted C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₇cycloalkyl, aryl, Het¹, Het²; R₁ may also be a radical of formula (R_{11a}R_{11b})NC(R_{10a}R_{10b})CR₉; t is 0, 1 or 2; R₂ is H or C₁₋₆alkyl; L is -C(=O)-, -O-C(=O)-, -NR₈-C(=O)-, -O-C₁₋₆alkanediyl-C(=O)-, -NR₈-C₁₋₆alkanediyl-C(=O)-, -S(=O)₂-, -O-S(=O)₂-, -NR₈-S(=O)₂; R₃ is C₁₋₆alkyl, aryl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₄alkyl, or aryl-C₁₋₄alkyl; R₄ is H, C₁₋₄alkylOC(=O), carboxyl, aminoC(=O), mono- or di(C₁₋₄alkyl)aminoC(=O), C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl or optionally substituted C₁₋₆alkyl; A is C₁₋₆alkanediyl, -C(=O)-, -C(=S)-, -S(=O)₂-, C₁₋₆alkanediyl-C(=O)-, C₁₋₆alkanediyl-C(=S)- or C₁₋₆alkanediyl-S(=O)₂; R₅ is H, OH, C₁₋₆alkyl, Het¹C₁₋₆alkyl, Het²C₁₋₆alkyl, optionally substituted amino-C₁₋₆alkyl; R₆ is C₁₋₆alkylO, Het¹, Het¹O, Het², Het²O, aryl, arylO, C₁₋₆alkyloxycarbonylamino or amino; and in case -A- is other than C₁₋₆alkanediyl then R₆ may also be C₁₋₆alkyl, Het¹C₁₋₄alkyl, Het¹OC₁₋₄alkyl, Het²C₁₋₄alkyl, Het²OC₁₋₄alkyl, arylC₁₋₄alkyl, arylOC₁₋₄alkyl or aminoC₁₋₄alkyl; whereby each of the amino groups in the definition of R₆ may optionally be substituted; R⁵ and -A-R⁶ taken together with the nitrogen atom to which they are attached may also form Het¹ or Het², R₁₂, is H, -NH₂, -NR⁵AR⁶, -C₁₋₆alkyl or alkyl-W-R₁₄, wherein said alkyl is optionally substituted with halogen, hydroxy, aryl, heteroaryl, Het¹, Het², or amino wherein said amino is optionally mono- or di-substituted with C₁₋₄alkyl and R₁₃ is H, C₁₋₆alkyl, optionally substituted by aryl, Het¹, Het², hydroxy, halogen, amino whereby the amino group may be optionally be mono- or di-substituted with C₁₋₄alkyl.

WO 03/076413 A1



ACTION

- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*